Biopharmaceutical Contract Manufacturing Market Size is Anticipated to Reach USD 63.9 Billion by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, given the increased approvals of biologics, growing complexity of drug synthesis and need for reducing time-to-market, the biopharmaceutical contract manufacturing market is well positioned for future growth.

Global Biopharmaceutical Contract Manufacturing Market Overview

The global biopharmaceutical contract manufacturing market is expected to reach USD 63.9 billion by 2035, growing at a CAGR of 8.3% during the forecast period till 2035.

Biopharmaceuticals are the medicinal / therapeutic products that are either manufactured using living organisms or semi-synthesized from biological sources. The rising prevalence of chronic diseases and shift towards advanced therapeutic modalities have significantly boosted demand for biologics. Consequently, numerous developers outsource manufacturing operations to third-party providers, enabling them to meet escalating needs of the industry. Notably, outsourcing business operations to third party developers and manufacturers provides excellent opportunities to access greater production capabilities and / or new products. With outsourcing becoming increasingly accepted as a viable and beneficial business model within this field, the global market for biopharmaceutical contract manufacturing will witness remarkable growth during the forecast period.

Browse ~200 figures and ~230 market data tables spread across ~575 pages and detailed Table of Content on “Global biopharmaceutical contract manufacturing market, till 2035 by Type of Service Offered (Drug Substance Manufacturing (API), and Drug Product Manufacturing (FDF)), Type of Biologic Manufactured (Antibodies, Proteins / Peptides, Vaccines, Cell Therapies, Gene Therapies and Other Biologics), Type of Expression System Used (Mammalian Expression Systems, Microbial Expression Systems and Other Expression Systems), Scale of Operation (Preclinical / Clinical Scale and Commercial Scale), Therapeutic Area (Oncological Disorders, Cardiovascular Disorders, Metabolic Disorders, Infectious Diseases, Autoimmune Disorders, Neurological Disorders, Genetic Disorders and Other Disorders), Company Size (Small Companies, Mid-sized Companies, and Large and Very Large Companies) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)” here: https://www.rootsanalysis.com/reports/biopharmaceutical-contract-manufacturing-market/250.html

Market Drivers

Several factors are propelling the growth of global biopharmaceutical contract manufacturing market. One of the key factors driving the future of market is the access to advanced technologies, such as single-use bioreactors, continuous perfusion processes, and AI-driven automation, without requiring substantial capital investments for in-house facilities. Further, these specialized CMOs invest heavily in next-generation infrastructure, providing technical edge that enhances yield, reduce contamination risks, enable faster scalability, and improve efficiency in biologics production. Owing to these benefits, more companies are anticipated to shift towards outsourcing biopharmaceutical manufacturing, leading to a significant increase in the market growth.

Market Restraints

While the global biopharmaceutical contract manufacturing market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. One of the primary challenges is the biological complexity and variability. Moreover, the dependency of biopharmaceutical contract manufacturers on the network of raw material suppliers, API producers and specialized equipment manufacturers make them vulnerable to global supply chain disruption. These factors collectively act as barriers to wider adoption, challenging the market’s ability to sustain its growth trajectory.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the global biopharmaceutical contract manufacturing market forward. One notable factor is the integration of artificial intelligence and machine learning in biopharmaceutical manufacturing processes, which has significantly resulted in enhanced efficiency, quality, and agility across various processes. These technologies enable real-time process monitoring, predictive maintenance, and automated quality control, which reduces the downtime and minimizes variability in biopharmaceutical production. Owing to these factors, it can be anticipated that the global biopharmaceutical contract manufacturing market will flourish remarkably in the foreseen future.

Global Biopharmaceutical Contract Manufacturing Market Segments

Based on the type of service offered, the market is segmented into drug substance (API) manufacturing, and drug product (FDF) manufacturing.

• The drug substance (API) manufacturing sub-segment led the global biopharmaceutical contract manufacturing market, capturing the largest revenue share of around 60% in the current year.
• Drug product (FDF) manufacturing sub-segment is anticipated to show the highest growth rate of 9.2%, during the forecast period.

Based on the type of biologic manufactured, the market is segmented into antibodies, proteins / peptides, vaccines, cell therapies, gene therapies and other biologics.

• The antibodies sub-segment led the global biopharmaceutical contract manufacturing market, capturing the largest revenue share of around 60% in the current year.
• The cell therapies sub-segment is anticipated to grow at an annualized rate of 15.9%, during the forecast period.

Based on the type of expression system used, the market is segmented into mammalian expression systems, microbial expression systems, and other expression systems.

• The mammalian expression systems sub-segment led the global biopharmaceutical contract manufacturing market, capturing the largest revenue share of more than 80% in the current year. Further, this segment is expected to grow at a higher annualized rate of 8.6%.
• This is primarily because of their human-like environment for protein processing, high yield and scalability, and proven safety across several biopharmaceuticals.

Based on the scale of operation, the market is segmented into preclinical / clinical scale and commercial scale.

• The commercial scale sub segment is expected to hold the majority share of global biopharmaceutical contract manufacturing market, capturing about 90% of revenue share in the current year.
• The preclinical / clinical scale sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 8.9% during the forecast period.

Based on the therapeutic area, the market is segmented into oncological disorders, cardiovascular disorders, metabolic disorders, infectious diseases, autoimmune disorders, neurological disorders, genetic disorders and other disorders.

• The oncological disorders sub segment is expected to hold the majority share of global biopharmaceutical contract manufacturing market, capturing about 35% of revenue share in the current year. Further, the market for oncological disorders is expected to grow with a higher annualized rate of 9.1% during the forecast period.
• This growth can be attributed to the fact that high-value biologics, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and cell / gene therapies, are used significantly to treat oncological disorders.

Based on the company size, the market is segmented into small companies, mid-sized companies, and large and very large companies.

• The large and very large companies sub segment is expected to hold the majority share of global biopharmaceutical contract manufacturing market, capturing around 80% revenue share in the current year.
• The small companies sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 13.9% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

• Asia-Pacific dominated the global biopharmaceutical contract manufacturing market and accounted for the largest revenue share (~45%) in the current year. Further, the market in Asia-Pacific is expected to grow at a higher annualized rate of 9.6%.
• This can be attributed to the fact that the number of manufacturing facilities in this region is relatively higher when compared to other regions.

Key Companies Profiled

The global biopharmaceutical contract manufacturing market report also includes detailed profiles of key companies (listed below) that are engaged in the biopharmaceutical contract manufacturing domain:

• AbbVie
• Agilent Technologies
• Boehringer Ingelheim
• Catalent
• Cipla
• Eurofins
• Fresenius Kabi
• Lonza
• Novartis
• Sandoz
• WACKER
• WuXi Biologics

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/biopharmaceutical-contract-manufacturing-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 1,500 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com